Nicole Merritt, PhD


Nicole Merritt
Postdoctoral Research Scholar
nicole-merritt@uiowa.edu

Department of Pathology
1194 Medical Laboratories
500 Newton Road
University of Iowa
Iowa City, IA 52242-1109

Lab: 319-384-1175

Hometown

Cedar Rapids, Iowa

Education

BA, Biology and Biochemistry, Wartburg College, Waverly, Iowa
PhD, Pharmacology, Creighton University, Omaha, Nebraska

Research Description

Investigating how dysregulation of the Hippo Pathway and activation of TAZ (WWTR1) and YAP1 contributes to sarcoma development and disease progression.

Publications

  1. Merritt NM, Fullenkamp CA, Hall SL, Qian Q, Desai C, Thomason J, Lambertz AM, Dupuy AJ, Darbro B, and Tanas MR. A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 2018; 9(60):31620-31636. https://doi.org/10.18632/oncotarget.25824
  2. Buchakjian MR, Merritt NM, Moose DL, Dupuy AJ, Tanas MR, Henry MD. 2017. A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging. PLoS ONE 12(8): e0183469. https://doi.org/10.1371/journal.pone.0183469
  3. Voss KA, Riley RT, Gardner NM, Gelineau-Van Waes J. 2017. Fumonisins In RC Gupta (Ed.), Reproductive and Developmental Toxicology, 2nd Ed, Chapter 47, pp.925-944. Academic Press. https://doi.org/10.1016/B978-0-12-804239-7.00047-0
  4. Gardner NM, Riley RT, Showker JL, Voss KA, Sachs AJ, Maddox JR, and Gelineau-van Waes JB. 2016. Elevated nuclear sphingoid base-1-phosphates and decreased histone deacetylase activity after fumonisin B1 treatment in mouse embryonic fibroblasts. Toxicology and Applied Pharmacology, 298: 56-65. PMID: 26905748. doi: 10.1016/j.taap.2016.02.018
  5. Gardner NM, Riley RT, Showker JL, Voss KA, Sachs AJ, Maddox JR, and Gelineau-van Waes JB. 2015. Elevated nuclear and cytoplasmic FTY720-phosphate in mouse embryonic fibroblasts suggests the potential for multiple mechanisms in FTY720-induced neural tube defects. Toxicological Sciences, 150: 161-168. PMID: 26719367. doi: 10.1093/toxsci/kfv321.
  6. Lizalek J, McKenna T, Huegel K, Marsh S, Carolan A, Kobliska A, Heying E, Gardner N Miller G, Kotecki A, Henningsen M, Lundt A, Farley J, and Ellerbroek S. 2015. Lysophosphatidic acid stimulates urokinase receptor (uPAR/CD87) in ovarian epithelial cancer cells. Anticancer Research, 35: 5263-5270. PMID: 26408685.
  7. Riley RT, Showker J, Lee C, Zipperer C, Mitchell T, Voss K, Zitomer N, Torres O, Matute J, Gregory S, Ashley-Koch A, Maddox J, Gardner N, and Gelineau-van Waes J. 2015. A Blood Spot Method for Detecting Fumonisin-Induced Changes in Putative Sphingolipid Biomarkers in LM/Bc Mice and Humans. Food Additives and Contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment, 32: 934-949.
  8. Gelineau-van Waes J, Rainey MA, Maddox JR, Voss KA, Sachs AJ, Gardner NM, Wilberding JD, and Riley RT. 2012. Increased sphingoid base-1-phosphates and failure of neural tube closure after exposure to fumonisin or FTY720. Birth Defects Research Part A: Clinical and molecular teratology, 94: 790-803. PMID: 22991331.
  9. Riley RT, Voss KA, Showker JL, Torres O, Matute J, Maddox JR, Rainey MA, Gardner NM, Sachs AJ, Gregory SG, Ashley-Koch AE, Krupp D, and Gelineau-van Waes J. 2012. Development of biomarkers to assess fumonisin exposure and birth defects. In EM Binder (Ed.), World Nutrition Forum 2012 (pp.249-256). Leicestershire, England: Anytime Publishing.